Melanoma patients may benefit from a new development. A vaccine has shown promise in preventing the disease from returning or spreading. It is tailored to each patient, taking into account unique mutations within their tumors.

The vaccine uses mRNA technology, similar to that used in certain coronavirus vaccines. It is being paired with another treatment in current studies.

Further details about the vaccine, including results from Phase 3 trials, are available from the companies involved, Moderna and Merck. The vaccine is said to be individualized, offering a potential new option for those who have had melanoma.